O-1821 – 5 mg

Brand:
Cayman
CAS:
35482-50-9
Storage:
-20
UN-No:
De Minimis - 1231 / 3

Abnormal cannabidiol is a synthetic regioisomer of cannabidiol that fails to elicit either central cannabinoid (CB1) or peripheral cannabinoid (CB2) receptors responsiveness and is without psychotropic activity. It induces endothelium-dependent vasodilation via a CB1/CB2/nitric oxide-independent mechanism.{11092} O-1821 is a cannabidiol analog with close structural similarity to O-1918 which is a selective antagonist of abnormal cannabidiol at the non-central cannabinoid (CB1)/peripheral cannabinoid (CB2) receptors endothelial receptor.{11761} O-1918 does not bind to CB1 or CB2 receptors at concentrations up to 30 µM and inhibits the vasorelaxant effects of abnormal cannabidiol in vitro and in whole animals.{11761} The biological activity of O-1821 has not been reported.  

 

Available on backorder

SKU: 10006804 - 5 mg Category:

Description

A cannabidiol analog with close structural similarity to O-1918, a selective antagonist of abnormal cannabidiol (Abn-CBD) at the non-CB1/CB2 endothelial receptor; O-1918 does not bind to CB1 or CB2 receptors at concentrations up to 30 µM and inhibits the vasorelaxant effects of Abn-CBD in vitro and in whole animals


Formal name: 5-methyl-2-[(1R,6R)-3-methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-1,3-benzenediol

Synonyms:  ​CBD-C1|Cannabidiorcin|Cannabidiorcol|Cannabidiorocol|CBDO

Molecular weight: 258.4

CAS: 35482-50-9

Purity: ≥97%

Formulation: A solution in methyl acetate


Product Type|Biochemicals||Research Area|Cardiovascular System|Vasculature|Vasoconstriction||Research Area|Neuroscience|Cannabinoid Research